NEW YORK — Luigi Mangione, 28, pleaded guilty on Friday to federal stalking-to-kill charges in the 2024 fatal shooting of UnitedHealthcare CEO Brian Thompson, a brazen act that has drawn national attention amid broader frustrations with the U.S. healthcare system. Mangione admitted in Manhattan federal court that he targeted and killed Thompson outside a Manhattan hotel on December 4, 2024, as the executive walked to an investor conference. His plea averted a closely watched federal trial and resolved one of two cases against him, though he still faces state murder charges in a trial scheduled for next month.
Mangione faces a maximum sentence of life in prison on the federal charges, with sentencing set for December 18. Prosecutors have indicated they will seek the maximum penalty, while his defense team has filed a motion to dismiss the state murder case on double jeopardy grounds, arguing that punishing him twice for the same conduct would violate New York law. The plea came after Mangione, dressed in beige prison attire, read a prepared statement in which he acknowledged shooting Thompson and expressed criticism of the U.S. health insurance industry.
Thompson’s widow, Paulette Thompson, and other family members were present in the courtroom when Mangione made his admission. According to reports, she became visibly emotional as Mangione stated, “I shot Mr. Thompson in Manhattan and he died.” The Thompson family later issued a statement calling the plea “an important step toward justice.”
Key Developments in the Case
Mangione’s guilty plea resolves the federal case but leaves unresolved the state-level murder charges, which his attorneys are attempting to dismiss. The motion argues that the federal and state prosecutions stem from the same conduct, violating protections against double jeopardy. Legal experts note that the success of this argument will depend on judicial interpretation of the charges and the specific circumstances of the case.
Prosecutors have emphasized that Mangione’s plea does not reflect any leniency or concession. Manhattan US Attorney Jamie McDonald stated, “No grievance or ideological cause can ever justify murder.” The federal government’s case included evidence such as surveillance footage and a 3D-printed gun recovered from Mangione’s possession at the time of his arrest in Pennsylvania five days after the shooting. Mangione’s lawyers have not publicly explained his decision to plead guilty, though filings suggest the move was strategic to focus on sentencing mitigation.
Motive and Background
In his court statement, Mangione cited years of frustration with the U.S. healthcare system, particularly his own experiences with back pain and interactions with insurers. He claimed to have posed as an investor to gather information about UnitedHealthcare’s conference before traveling to New York and manufacturing the weapon used in the shooting. While Mangione was not a customer of UnitedHealthcare, the company has faced widespread criticism for claim denials and industry practices.
The killing of Thompson, a prominent figure in the healthcare sector, sparked immediate debate over the state of the industry and the ethics of targeted violence as a form of protest. Some observers framed Mangione’s actions as a distorted reflection of public anger toward insurers, while others condemned the violence outright. The case has also drawn attention to the broader issue of healthcare-related grievances, with Mangione’s supporters—dubbed “Mangionistas” by media—viewing him as a symbol of resistance against systemic failures.
Ongoing Legal and Emotional Fallout
Thompson’s family has endured additional hardships in the aftermath of his death, including bomb threats and harassment directed at their homes in Minnesota within 24 hours of the shooting. Investigators later determined the threats were not credible, but the episode underscored the emotional toll on the family. Paulette Thompson’s rare public appearance in court marked the first time she confronted Mangione directly since the killing.
Legal analysts note that Mangione’s federal sentencing will hinge on factors such as his acceptance of responsibility, the absence of a plea deal, and the judge’s discretion. The state trial, if it proceeds, could result in a separate sentence, though his defense is expected to vigorously contest its validity. The case remains a focal point for discussions about healthcare policy, criminal justice, and the boundaries of protest in the United States.